Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.56 |
| ▸ | HTR3A | P46098 | 6/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699736 | 0.81 | HTR1A (0.57) | HTR1AHTR3ASIGMAR1HTR2CMEN1 | |
| SCHEMBL4699622 | 0.74 | SIGMAR1 (0.46) | HTR1AHTR3ASIGMAR1DHFR | |
| SCHEMBL4702082 | 0.74 | HTR1A (0.50) | HTR1AHTR3ASIGMAR1HTR2CHTR6 | |
| SCHEMBL4702827 | 0.74 | DRD2 (0.51) | HTR1AHTR3ASIGMAR1MEN1KMT2A | |
| SCHEMBL4702868 | 0.73 | SIGMAR1 (0.51) | HTR1AHTR3ASIGMAR1HTR2CHTR6 | |
| SCHEMBL4703103 | 0.73 | HTR1A (0.57) | HTR1AHTR3ASIGMAR1HTR2CHTR6 | |
| SCHEMBL737743 | 0.73 | OPRM1 (0.57) | SIGMAR1HTR2CMEN1KMT2AOPRM1 | |
| SCHEMBL4702507 | 0.72 | SIGMAR1 (0.45) | HTR1AHTR3ASIGMAR1HTR2CHTR6 | |
| SCHEMBL4702717 | 0.72 | SIGMAR1 (0.45) | HTR1AHTR3ASIGMAR1HTR2CHTR6 | |
| Hydrochloric Acid SCHEMBL30206700 | 0.72 | OPRM1 (0.56) | SIGMAR1HTR2CMEN1KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100384822-C | 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | LUNDBECK & CO AS H (DK) | 2008-04-30 | — | — | CN | disclosed |
| EP-1613594-B1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-03-26 | — | — | EP | disclosed |
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2007-07-26 | — | — | US | disclosed |
| EP-1613594-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087662-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | TPH1, HTR2C, HTR1D | HTR1A 4/4885HTR3A 11/4885SIGMAR1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.